New Hope on the Horizon - Advances in the Diagnosis and Treatment of Idiopathic Hypersomnia
Idiopathic hypersomnia (IH) is a chronic neurological disorder that has significant impacts on daily functioning, with symptoms that include, but often go beyond excessive daytime sleepiness (EDS).
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.75 ACPE Pharmacy
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC
  • 1.75 Participation
Cost $0.00
18th Annual CMHC On Demand
The recordings from the 18th Annual meeting are now available. 
Category
  • CMHC
Format
  • Conference / meeting
  • Video
Credits
  • 19.25 ACPE Pharmacy
  • 19.25 AMA PRA Category 1 Credit™
  • 19.25 ANCC
  • 19.25 CDE
  • 19.25 Participation
Cost $0.00
Clinical Brief: The Burden of Resistant Hypertension in Women - Novel and Emerging Approaches to Improve Outcomes
This clinical brief was developed from a presentation at the 2023 Women's Health and Wellness Masterclass held August 2023 in Dana Point, CA.
Category
  • CMHC
Format
  • Monograph
Credits
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
Cost $0.00
Tackling the Disproportionate Burden of Resistant Hypertension in Black Adults
This activity consists of a recorded presentation at the 18th annual CMHC Annual Congress held from October 18-21, 2023, in Boston, MA.
Category
  • CMHC
Format
  • Video
Credits
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
Cost $0.00
Challenges and Solutions in Lipid-Lowering Therapy in Women: From Gaps to Practice-Changing Advances
Atherosclerotic cardiovascular disease (ASCVD) events are among the leading causes of death in women in the US and globally.
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 Participation
Cost $0.00
Webcast: Addressing and Treating Iron Deficiency to Improve Symptoms and Outcomes in Patients with Heart Failure
Iron deficiency (ID) with or without anemia is a common comorbidity in patients with heart failure (HF), and it can have significant impacts on morbidity and mortality.
Category
  • CMHC
Format
  • Video
  • Webinar recorded
Credits
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Cost $0.00
Escape Room Experience: Individualizing Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes
The coexistence of type 2 diabetes and chronic kidney disease significantly exacerbates cardiovascular and renal morbidity and mortality compared to either condition alone. Even with the advent of newer therapies in patients with T2D and CKD, such as sodium-glucose cotransporter-2 (SGLT-2) inhibi
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Cost $0.00
Breaking Through Inertia: How to Initiate and Maintain Insulin Therapy in Patients with Type 2 Diabetes
This interactive infographic covers a variety of topics surrounding the role of insulin therapy in type 2 diabetes (T2D) management, including practical pearls for initiation and maintenance of insulin therapy, how insulin therapy fits in with other T2D treatment options, a
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.50 AAFP
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Cost $0.00
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25-30% of people in the United States and can often progress to Metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis.
Category
  • CMHC
  • TME
Format
  • Self-study / Enduring
Credits
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
Cost $0.00
Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk: A Paradigm Shift
Effectively and safely lowering LDL-C is essential to prevent and reduce the risk of recurrent ASCVD events.
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 CDE
  • 1.50 Participation
Cost $0.00

Pages